Skip to main content
Neurospine logoLink to Neurospine
. 2026 Oct 31;23(4):1032–1034. doi: 10.14245/ns.26521506.0753

Reply to Letter to the Editor Regarding “Agonist-Induced Activation of Transient Receptor Potential Vanilloid 4 Promotes Autophagy and Extracellular Matrix Synthesis in the Rat Intervertebral Disc”

Kohei Kuroshima 1, Yoshiki Takeoka 1,✉, Takashi Yurube 1, Takeru Tsujimoto 1, Yutaro Kanda 1, Kunihiko Miyazaki 1, Hiroki Ohnishi 1, Tomoya Matsuo 1, Masao Ryu 1, Naotoshi Kumagai 1, Yoshiaki Hiranaka 1, Masahiko Furuya 1, Daisuke Nakagawa 1, Yu Inoue 1, Ryosuke Kuroda 1, Kenichiro Kakutani 1
PMCID: PMC13745921  PMID: 43000818

We sincerely appreciate the author’s thoughtful and well-referenced commentary on our recent article [1]. The commentary highlights important methodological considerations regarding the assessment of autophagy, causal validation of the proposed signaling pathway, and definition of the therapeutic window for transient receptor potential vanilloid 4 (TRPV4) activation.

We agree that changes in LC3-II and p62/SQSTM1 are static measurements and cannot, by themselves, definitively demonstrate increased autophagic flux. In our study, increased LC3-II, decreased p62/SQSTM1, enhanced AMP-activated protein kinase (AMPK) phosphorylation, suppression of mechanistic target of rapamycin (mTOR)-related signaling, and favorable changes in extracellular matrix (ECM) metabolism were collectively interpreted as being consistent with enhanced autophagic activity. However, because lysosomal turnover was not directly assessed, impaired autophagosome degradation or altered lysosomal clearance cannot be completely excluded. Dynamic flux analyses using lysosomal inhibitors such as bafilomycin A1 or chloroquine, together with tandem mCherry-GFP-LC3 reporters, would more directly distinguish autophagosome formation from lysosomal degradation [2-4]. Our findings should therefore be interpreted as evidence of activation of autophagy-related signaling and changes in autophagy-associated markers, rather than as definitive evidence of enhanced autophagic flux.

A further important point is that the observed sequence of intracellular Ca2+ influx, AMPK phosphorylation, mTOR suppression, changes in autophagy-associated markers, and ECM preservation does not establish the necessity of each component of the proposed pathway. The present study was designed primarily as a pharmacological gain-of-function investigation of the biological effects of TRPV4 activation in vitro and in vivo. Accordingly, the proposed Ca2+–AMPK–mTOR–autophagy axis remains biologically plausible but has not yet been fully established as a causal pathway. Nevertheless, our findings complement those of our previous loss-of-function study [5], in which TRPV4 knockdown reduced autophagy-related responses and ECM synthesis and accelerated progressive structural disc disruption. Together, these reciprocal observations support a role for TRPV4 in intervertebral disc homeostasis, although they do not establish that its protective effects are mediated exclusively through this pathway.

More definitive causal validation will require pathway-interruption and rescue experiments. Selective TRPV4 antagonism, intracellular Ca2+ chelation, pharmacological or genetic inhibition of AMPK, restoration of mTOR activity, and suppression of essential autophagy-related genes such as ATG5 or ATG7 would help determine whether the anabolic and cytoprotective effects of TRPV4 activation depend on this specific signaling axis. Such experiments may also clarify whether parallel signaling pathways contribute to the observed ECM-preserving effects.

The commentary also rightly emphasizes the importance of defining the therapeutic window of TRPV4 activation. In our in vitro dose-response experiments, 10 nM GSK1016790A was selected because it elicited a robust Ca2+ response without detectable cytotoxicity after 24 hours, whereas concentrations of 20 nM or higher reduced cell viability. This finding suggests a concentration-dependent transition from adaptive signaling to cellular injury. In addition, our in vivo experiments were limited to a single concentration, a single intradiscal administration, and a temporary static-compression model. Therefore, the present study does not establish an optimal therapeutic regimen. Future investigations should systematically evaluate different concentrations, exposure durations, repeated-administration protocols, and mechanical and osmotic conditions. Relevant safety and efficacy outcomes should include sustained intracellular Ca2+ elevation, inflammatory signaling, apoptosis, senescence, ECM metabolism, and structural disc changes.

Overall, our study provides initial evidence that moderate agonist-induced TRPV4 activation is associated with AMPK/mTOR signaling, autophagy-related responses, ECM preservation, and attenuation of experimental disc degeneration. Nevertheless, dynamic measurements of autophagic flux, direct pathway-interruption studies, and detailed dose- and context-dependent analyses will be required to establish causality and evaluate therapeutic applicability more rigorously.

We once again thank the author for this valuable commentary, which enhances the interpretation of our findings and advances the scholarly discussion regarding the safe and effective therapeutic targeting of TRPV4 in intervertebral disc degeneration.

Footnotes

Conflict of Interest

YT, TY, and KKakutani are faculty members of an endowed course supported by Surgical Spine Inc. and SMI Japan Inc. The other authors have nothing to disclose.

REFERENCES

  • 1.Kuroshima K, Takeoka Y, Yurube T, et al. Agonist-induced activation of transient receptor potential vanilloid 4 promotes autophagy and extracellular matrix synthesis in the rat intervertebral disc. Neurospine. 2026;23:347–64. doi: 10.14245/ns.2551582.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3:452–60. doi: 10.4161/auto.4451. [DOI] [PubMed] [Google Scholar]
  • 3.Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3:542–5. doi: 10.4161/auto.4600. [DOI] [PubMed] [Google Scholar]
  • 4.Mauthe M, Orhon I, Rocchi C, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14:1435–55. doi: 10.1080/15548627.2018.1474314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Matsuo T, Takeoka Y, Yurube T, et al. Transient receptor potential vanilloid 4 knockdown decreases extracellular matrix synthesis via autophagy suppression in the rat intervertebral disc. JOR Spine. 2025;8:e70046. doi: 10.1002/jsp2.70046. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neurospine are provided here courtesy of Korean Spinal Neurosurgery Society

RESOURCES